News
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary - The oncology landscape is being pulled ...
Subcutaneous isatuximab administered via an on-body injector appears to be as safe and effective as intravenous isatuximab in patients with relapsed or refractory multiple myeloma.
A recent webinar from BD shared important insights into patient fear and anxiety over self-injection and how the right device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback